Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events

[11] De Porre P(2015)Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: A survey capturing experiences from a diverse sample of UK patients Value in Health 18 1152-1157

[12] Kheoh T(2016)Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer Indian Journal of Urological Society of India 32 257-261

[13] Park Y(1998)Variations in population health status: Results from a United Kingdom national questionnaire survey BMJ: British Medical Journal 316 736-741

[14] Todd M(2011)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Quality of Life Research 20 1727-1736

[15] Chi K(2010)Protocols for time tradeoff valuations of health states worse than dead: A literature review Medical Decision Making 30 610-619

[16] Sartor O(2006)Exploring challenges to TTO utilities: Valuing states worse than dead Health Economics 15 393-402

[17] Flood E(1997)Modeling valuations for EuroQol health states Medical Care 35 1095-1108

[18] Beusterien K(2018)Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial The Lancet Oncology 19 194-206

[19] Park J(2013)Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial The Lancet Oncology 14 149-158

[20] Webb I(2018)Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer Journal of Clinical Oncology 36 1088-1095

[11] De Porre P(2015)Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: A survey capturing experiences from a diverse sample of UK patients Value in Health 18 1152-1157

[12] Kheoh T(2016)Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer Indian Journal of Urological Society of India 32 257-261

[13] Park Y(1998)Variations in population health status: Results from a United Kingdom national questionnaire survey BMJ: British Medical Journal 316 736-741

[14] Todd M(2011)Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Quality of Life Research 20 1727-1736

[15] Chi K(2010)Protocols for time tradeoff valuations of health states worse than dead: A literature review Medical Decision Making 30 610-619

[16] Sartor O(2006)Exploring challenges to TTO utilities: Valuing states worse than dead Health Economics 15 393-402

[17] Flood E(1997)Modeling valuations for EuroQol health states Medical Care 35 1095-1108

[18] Beusterien K(2018)Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): An international, randomised phase 3 trial The Lancet Oncology 19 194-206

[19] Park J(2013)Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial The Lancet Oncology 14 149-158

[20] Webb I(2018)Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer Journal of Clinical Oncology 36 1088-1095